EGFR and non-small cell lung carcinoma: The subsequent development of precision therapeutics that could target and override the oncogenic action of EGFR-mutations has revolutionized the management and prognosis of individuals with EGFR-mutation-positive NSCLC (EGFRm+) [1,4,5,6,7,8].